DALLAS, Sept. 26, 2019 /PRNewswire/ -- Phynd Technologies, Inc., a leading health care provider information management platform, announced that it has joined the

CAMBRIDGE, Mass., Sept. 26, 2019 /PRNewswire/ -- In a new study just published in JCO Clinical Cancer Informatics, researchers from the Massachusetts Ins

GERMANTOWN, Md., Sept. 26, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced

LOS ANGELES, Sept. 26, 2019 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager (TriKE™) platform, announced today that Dr. Jeffrey Miller and colleagues from the University of Minnesota wil

CHICAGO and SAN FRANCISCO and VERNON HILLS, Ill., Sept. 26, 2019 /PRNewswire/ -- GTCR and Golden Gate Capital announced today that they have signed a definitive agreement to recapitalize Cole-Parmer Instrument Company ("Cole-Parmer", or the "Company") alongside CEO Bernd Brust and the Cole-Parmer m

MARTINSRIED, Germany and MUNICH, Sept. 26, 2019 /PRNewswire/ -- iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on novel immune checkpoint targets, announced today the presentation of two posters at the Fifth International Cancer lmmunotherapy Conference (CICON 2019) which showcases the compan

SAN FRANCISCO, Sept. 26, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today a presentation of new clinical data for bempegaldesleukin (bempeg, NKTR-214) in combination with nivolumab in patients with advanced or metastatic triple-negative breast cancer (TNBC) at the 2019 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in

FAIRFAX, Va., Sept. 26, 2019 /PRNewswire/ -- Pyramid Systems, a women-owned small business providing technology solutions to the federal government, is excited to announce that Chris Bishop has joined the company as its Chief Growth Officer. Bishop, a recognized industry growth and tech leader, will develop and implement Pyramid's organic a

OLDWICK, N.J., Sept. 26, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the appointment of Sean Doherty to the Company's Board of Directors. Mr. Doherty is the Executive Chairman of the JDRF T1D Fund

BOSTON, Sept. 26, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced that Proteostasis management will present at the 2019 Cantor Glob